I'm still pondering whether to take the plunge with EMC. Need to free up some funds from elsewhere in order to do so though, will probably drop a couple lame ducks and move it here.
In preparation to do so I had a short back and forth via email with some questions and answers from Ross.
Nothing really ground breaking, with these sort of cold calls most of the time it's "refer to page xx" and you can only hope for one or two small tid-bits that you can try to read into.
In case anyone is interested the Q&A's are below:
- In some previous documents/presentations it was mentioned that first orders/commercialization was looking to take place in 2011/2012. Could you provide an explanation as to the delay?
Emefcy is a technology based company, pioneering disruptive technologies. Emefcy has never compromised on the reliability and robustness of its systems. Reliability tests for over a year of continuous operation has enabled the recent release to market of the SABRE products which is expected to generate revenues in 2016.
The Investor Presentation released to ASX on 16 October 2015 noted on slide 13 that the first commercial conditional sales contract for SABRE had already been achieved. A further update on this first sale will be provided later in this month.
- can you explain briefly the difference between SABRE and SABRE2/SUBRE?
SABRE 2 and SUBRE represent future product developments and are evolutions of SABRE 1. SABRE 2 is a larger scale module. SUBRE is a drop-in version, designed to retrofit the unique SABRE membrane directly into an existing waste water treatment facility.
- Can you provide some updates on the sales channels of SABRE that have been explored? (interest from wider market or other customers?)
Emefcy’s marketing plans and sales channels Information are described on page 23 of the Prospectus. Any significant developments on sales will be released to the market.
- Would be great if you could elaborate on the patent situation;
- Are the pending patents completely standalone to the founders work at Aqwise?
As described in the Intellectual Property Report included in the Prospectus (page 70), all patents are owned by Emefcy Limited (Israel).
In one interview there was the following quote: "We didn't invent anything scientifically new," says Ely Cohen, vice president of marketing and business development for the four-year-old company." If there is essentially nothing new could you provide an idea (brief) what the patent is for/covers?
The Company has developed significant intellectual property and protected this with patent applications and patents. The authors of the Intellectual property Report in the Prospectus note (page 70): “…we believe that Emefcy enjoys and will enjoy very broad patent protection over its technologies.”
Are there any legacy agreements (patent, commercial or otherwise) between the founders of Emefcy and their previous life at Aqwise?
No
(20min delay)